Aquestive Therapeutics (AQST) Accounts Payables (2017 - 2026)

Aquestive Therapeutics' Accounts Payables history runs 10 years deep, the most recent figure standing at $11.9 million for Q1 2026.

• On a quarterly basis, Accounts Payables fell 3.18% year-over-year to $11.9 million in Q1 2026; TTM through Mar 2026 was $11.9 million, a 3.18% decrease from a year earlier, with the FY2025 full-year figure at $29.9 million, up 190.29% from the prior year.
• Accounts Payables retreated to $11.9 million in Q1 2026 per AQST's latest filing, from $29.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $29.9 million in Q4 2025 and bottomed at $5.7 million in Q2 2024.
• The 5-year median for Accounts Payables is $10.5 million (2024), against an average of $11.3 million.
• Across the five-year window, Accounts Payables plunged 46.71% in 2024 and surged 190.29% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $9.9 million in 2022, then decreased by 10.26% to $8.9 million in 2023, then climbed by 15.25% to $10.3 million in 2024, then jumped by 190.29% to $29.9 million in 2025, then sank by 60.19% to $11.9 million in 2026.
• Per Business Quant, the three latest AQST Accounts Payables figures stand at $11.9 million (Q1 2026), $29.9 million (Q4 2025), and $10.9 million (Q3 2025).